Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
As reported by TMR, the global psoriasis treatment market is prognosticated to exhibit a 5.10% CAGR over the forecast period from 2016 to 2024. The market was estimated to be worth US$7.8 bn in 2015 and is forecasted to reach US$12.1 bn by 2024.
The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.
The Advisory Council on the Implementation of National Pharmacare's Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.1
Celltrion Healthcare recently presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with RA during the treatment period of one year.
Biogen Inc. (Nasdaq: BIIB) today announced that it will present new data at the European Congress of Rheumatology (EULAR) 2019 in Madrid, Spain (June 12-15). The abstracts include real-world data from the company’s biosimilar anti-TNF portfolio, which includes BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab).
On May 27th, the Government of British Columbia (B.C.) announced a policy that will forcibly switch thousands of patients with serious, chronic conditions from their current biologic medicines to lower-cost "biosimilar" treatments, effective November 25th, 2019.
Pfizer, Inc. PFE expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Prevnar.
Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc., recently announced the launch of a medical pharmacy solution targeting oncology therapeutic biosimilars.
|
|
|
|
|
|
|
|
|